{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["CF_E"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":0,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"CF_E","index":0,"n_rows":56,"n_cols":6,"rows_kept":56,"cut":false,"hidden":false,"merged":[[2,1,2,2]]}
[]
[null,"Consolidated statement of cash flows (IFRS)"]
[null,"from 1 October 2017 to 30 September 2018"]
[null,null,"2017/18\n1 Oct 17 to 30 Sep 18","2016/17\n1 Oct 16 to 30 Sep 17"]
[null,null,"€ k","€ k"]
[null,"Cash flows from operating activities:"]
[null,"Consolidated profit",{"$f":"126310-233+153","v":126230},135778]
[null,"Adjustments to reconcile consolidated profit to net cash \nprovided by / (used in) operating activities"]
[null,"Income taxes",{"$f":"53106-153","v":52953},52778]
[null,"Interest income / expenses",1680,1759]
[null,"       Results from other investments ",-34,-39]
[null,"Result from disposal of legal entity / hydrophilic IOL business Aaren Scientific Inc.",-2527,-7478]
[null,"Depreciation and amortisation",31282,24235]
[null,"Gains / losses on disposal of fixed assets ",2454,249]
[null,"       Dividends received",34,25]
[null,"Interest received",{"$f":"933+13","v":946},770]
[null,"Interest paid",{"$f":"-1952+13-1","v":-1940},-1559]
[null,"Refunded income taxes",2583,8700]
[null,"Income taxes paid",-50947,-63430]
[null,"Changes in working capital:"]
[null,"Trade receivables",{"$f":"535+51-699","v":-113},-48981]
[null,"Inventories",-11758,-33381]
[null,"Other assets",{"$f":"5816+699","v":6515},-18874]
[null,"Trade payables",{"$f":"862-51+109+1","v":921},15271]
[null,"Provisions and financial liabilities",{"$f":"22419-0-26","v":22393},-26704]
[null,"Other liabilities",6535,-1387]
[null,"Total adjustments",{"$f":"SUM(C9:C26)","v":60977},{"$f":"SUM(D9:D26)","v":-98046}]
[null,"Net cash provided by / (used in) operating activities",{"$f":"+C7+C27","v":187207},{"$f":"+D7+D27","v":37732}]
[null,"Cash flows from investing activities::"]
[null,"Investment in property, plant and equipment",{"$f":"-16426-109","v":-16535},-13656]
[null,"Investment in other intangible assets",-18221,-25366]
[null,"Proceeds from fixed assets",467,489]
[null,"Proceeds from sale of investments",0,16]
[null,"Payments for other loans",0,-4074]
[null,"Investment/ divestment in securities",3220,-4413]
[null,"Purchase of shares in affiliated non-consolidated companies",0,-12181]
[null,"Purchase of shares in affiliated consolidated companies, net of cash acquired",-353,-6035]
[null,"Proceeds from disposal of legal entity / hydrophilic IOL business Aaren Scientific Inc.",2548,9289,null,"incl sale of subsidiary Hexavision"]
[null,"Net cash provided by / (used in) investing activities",{"$f":"SUM(C30:C38)","v":-28874},{"$f":"SUM(D30:D38)","v":-55931}]
[null,"Cash flows from financing activities:"]
[null,"Proceeds from / (repayment of) current liabilities to banks",-102,219]
[null,"Proceeds from / (repayment of) non-current liabilities to banks",-482,-466]
[null,"(Increase) / decrease in treasury receivables",-33663,-277249]
[null,"Increase / (decrease) in treasury payables",-65315,45234]
[null,"Increase / (decrease) in liabilities due to finance lease",-2932,-2876]
[null,"      Dividend payments to shareholders of Carl Zeiss Meditec AG",-49192,-37565]
[null,"Dividend payments to non-controlling interests",-5551,-26264]
[null,"Proceeds from capital increase (net)",0,{"$f":"(8130.96*38.94)-(8130.96*38.94)*0.005","v":315036.48448799993}]
[null,"Payments of costs in connection with capital increase ",0,-1575]
[null,"Net cash provided by / (used in) financing activities",{"$f":"SUM(C41:C49)","v":-157237},{"$f":"SUM(D41:D49)","v":14494.484487999929}]
[null,"Effect of exchange rate fluctuation on cash and cash equivalents",-345,-1080]
[null,"Effect of changes in scope of consolidation on cash and cash equivalents",{"$f":"1680+322","v":2002},0]
[null,"Net increase / (decrease)  in cash and cash equivalents",{"$f":"+C28+C39+C50+C51+C52","v":2753},{"$f":"+D28+D39+D50+D51","v":-4784.5155120000709}]
[null,"Cash and cash equivalents, beginning of reporting period",3925,8710]
[null,"Cash and cash equivalents, end of reporting period",{"$f":"+C53+C54","v":6678},{"$f":"+D53+D54","v":3925.4844879999291}]
[null,"The following notes are an integral part of the audited consolidated financial statements."]